{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:39:14Z","timestamp":1792931954289,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","award":["Simona Caruso"],"award-info":[{"award-number":["Simona Caruso"]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Healthy Ministry","award":["GR-2016-02364546"],"award-info":[{"award-number":["GR-2016-02364546"]}]},{"name":"Italian Healthy Ministry","award":["RCR-2019-23669115"],"award-info":[{"award-number":["RCR-2019-23669115"]}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["INCAR project"],"award-info":[{"award-number":["INCAR project"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["9962"],"award-info":[{"award-number":["9962"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21979"],"award-info":[{"award-number":["21979"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["116026"],"award-info":[{"award-number":["116026"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["116026"],"award-info":[{"award-number":["116026"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR CN3"],"award-info":[{"award-number":["PNRR CN3"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes in patients with relapsed\/refractory disease, despite the improvements in intensive standard therapy. The leukaemic cells of paediatric AML patients show high expression of the CD123 antigen, and this finding provides the biological basis to target CD123 with the chimeric antigen receptor (CAR). However, CAR.CD123 therapy in AML is hampered by on-target off-tumour toxicity and a long \u201cvein-to-vein\u201d time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed an off-the-shelf product based on allogeneic natural killer (NK) cells derived from the peripheral blood of healthy donors and engineered them to express a second-generation CAR targeting CD123 (CAR.CD123).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CAR.CD123-NK cells showed significant anti-leukaemia activity not only in vitro against CD123\n                      <jats:sup>+<\/jats:sup>\n                      AML cell lines and CD123\n                      <jats:sup>+<\/jats:sup>\n                      primary blasts but also in two animal models of human AML-bearing immune-deficient mice. Data on anti-leukaemia activity were also corroborated by the quantification of inflammatory cytokines, namely granzyme B (Granz B), interferon gamma (IFN-\u03b3) and tumour necrosis factor alpha (TNF-\u03b1), both in vitro and in the plasma of mice treated with CAR.CD123-NK cells.\n                    <\/jats:p>\n                    <jats:p>\n                      To evaluate and compare the on-target off-tumour effects of CAR.CD123-T and NK cells, we engrafted human haematopoietic cells (hHCs) in an immune-deficient mouse model. All mice infused with CAR.CD123-T cells died by Day 5, developing toxicity against primary human bone marrow (BM) cells with a decreased number of total hCD45\n                      <jats:sup>+<\/jats:sup>\n                      cells and, in particular, of hCD34\n                      <jats:sup>+<\/jats:sup>\n                      CD38\n                      <jats:sup>\u2212<\/jats:sup>\n                      stem cells. In contrast, treatment with CAR.CD123-NK cells was not associated with toxicity, and all mice were alive at the end of the experiments. Finally, in a mouse model engrafted with human endothelial tissues, we demonstrated that CAR.CD123-NK cells were characterized by negligible endothelial toxicity when compared to CAR.CD123-T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data indicate the feasibility of an innovative off-the-shelf therapeutic strategy based on CAR.CD123-NK cells, characterized by remarkable efficacy and an improved safety profile compared to CAR.CD123-T cells. These findings open a novel intriguing scenario not only for the treatment of refractory\/resistant AML patients but also to further investigate the use of CAR-NK cells in other cancers characterized by highly difficult targeting with the most conventional T effector cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-022-01376-3","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T07:03:19Z","timestamp":1667631799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia"],"prefix":"10.1186","volume":"15","author":[{"given":"Simona","family":"Caruso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Del Bufalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselia","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Donsante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Manni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Guercio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Pezzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Iaffaldano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Alessandro","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Sinibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Di Cecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pitisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Velardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Algeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Riminucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Quintarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"key":"1376_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"1376_CR2","doi-asserted-by":"publisher","first-page":"720692","DOI":"10.3389\/fphar.2021.720692","volume":"12","author":"A Hernandez-Lopez","year":"2021","unstructured":"Hernandez-Lopez A, Tellez-Gonzalez MA, Mondragon-Teran P, Meneses-Acosta A. Chimeric antigen receptor-T cells: a pharmaceutical scope. Front Pharmacol. 2021;12:720692.","journal-title":"Front Pharmacol"},{"key":"1376_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33:64\u201374.","journal-title":"Leukemia"},{"key":"1376_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40259-021-00477-8","volume":"35","author":"S Fiorenza","year":"2021","unstructured":"Fiorenza S, Turtle CJ. CAR-T cell therapy for acute myeloid leukemia: preclinical rationale, current clinical progress, and barriers to success. BioDrugs. 2021;35:281\u2013302.","journal-title":"BioDrugs"},{"key":"1376_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cyto.b.21745","volume":"96","author":"AE Bras","year":"2019","unstructured":"Bras AE, et al. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytom B Clin Cytom. 2019;96:134\u201342.","journal-title":"Cytom B Clin Cytom"},{"key":"1376_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030496","author":"VM Perriello","year":"2021","unstructured":"Perriello VM, et al. CD123 is consistently expressed on NPM1-mutated AML cells. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13030496.","journal-title":"Cancers"},{"key":"1376_CR7","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","volume":"100","author":"U Testa","year":"2002","unstructured":"Testa U, et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980\u20138.","journal-title":"Blood"},{"key":"1376_CR8","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fonc.2019.01358","volume":"9","author":"S Yao","year":"2019","unstructured":"Yao S, et al. Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML. Front Oncol. 2019;9:1358.","journal-title":"Front Oncol"},{"key":"1376_CR9","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.2147\/OTT.S205678","volume":"12","author":"Y Sun","year":"2019","unstructured":"Sun Y, Wang S, Zhao L, Zhang B, Chen H. IFN-gamma and TNF-alpha aggravate endothelial damage caused by CD123-targeted CAR T cell. Onco Targets Ther. 2019;12:4907\u201325.","journal-title":"Onco Targets Ther"},{"key":"1376_CR10","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730\u20138.","journal-title":"J Clin Oncol"},{"key":"1376_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/MOH.0000000000000190","volume":"22","author":"A Mardiros","year":"2015","unstructured":"Mardiros A, Forman SJ, Budde LE. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol. 2015;22:484\u20138.","journal-title":"Curr Opin Hematol"},{"key":"1376_CR12","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill S, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123:2343\u201354.","journal-title":"Blood"},{"key":"1376_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1376_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.17662","volume":"194","author":"MR Hines","year":"2021","unstructured":"Hines MR, et al. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol. 2021;194:701\u20137.","journal-title":"Br J Haematol"},{"key":"1376_CR15","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"key":"1376_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"1376_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101702","author":"S Sivori","year":"2019","unstructured":"Sivori S, et al. NK cell-based immunotherapy for hematological malignancies. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8101702.","journal-title":"J Clin Med"},{"key":"1376_CR18","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/eji.202049028","volume":"51","author":"L Quatrini","year":"2021","unstructured":"Quatrini L, et al. Human NK cells, their receptors and function. Eur J Immunol. 2021;51:1566\u201379.","journal-title":"Eur J Immunol"},{"key":"1376_CR19","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1126\/science.1103478","volume":"306","author":"E Vivier","year":"2004","unstructured":"Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science. 2004;306:1517\u20139.","journal-title":"Science"},{"key":"1376_CR20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","volume":"6","author":"W Wang","year":"2015","unstructured":"Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6:368.","journal-title":"Front Immunol"},{"key":"1376_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00651.x","volume":"224","author":"A Moretta","year":"2008","unstructured":"Moretta A, Locatelli F, Moretta L. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev. 2008;224:58\u201369.","journal-title":"Immunol Rev"},{"key":"1376_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41375-019-0613-7","volume":"34","author":"C Quintarelli","year":"2020","unstructured":"Quintarelli C, et al. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia. Leukemia. 2020;34:1102\u201315.","journal-title":"Leukemia"},{"key":"1376_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1053\/j.seminhematol.2020.10.004","volume":"57","author":"S Caruso","year":"2020","unstructured":"Caruso S, et al. NK cells as adoptive cellular therapy for hematological malignancies: advantages and hurdles. Semin Hematol. 2020;57:175\u201384.","journal-title":"Semin Hematol"},{"key":"1376_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01083-5","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021. https:\/\/doi.org\/10.1186\/s13045-021-01083-5.","journal-title":"J Hematol Oncol"},{"key":"1376_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353.","journal-title":"N Engl J Med"},{"key":"1376_CR26","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2007.08.025","volume":"131","author":"B Sacchetti","year":"2007","unstructured":"Sacchetti B, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131:324\u201336.","journal-title":"Cell"},{"key":"1376_CR27","doi-asserted-by":"crossref","unstructured":"Quintarelli, C. et al. Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. J Immunother Cancer. 2021; 9.","DOI":"10.1136\/jitc-2020-001514"},{"key":"1376_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-1-60761-786-0_7","volume":"651","author":"A Di Stasi","year":"2010","unstructured":"Di Stasi A, De Angelis B, Savoldo B. Gene therapy to improve migration of T cells to the tumor site. Methods Mol Biol. 2010;651:103\u201318.","journal-title":"Methods Mol Biol"},{"key":"1376_CR29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3324\/haematol.2019.231183","volume":"106","author":"M Guercio","year":"2021","unstructured":"Guercio M, et al. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells. Haematologica. 2021;106:987\u201399.","journal-title":"Haematologica"},{"key":"1376_CR30","doi-asserted-by":"publisher","first-page":"755639","DOI":"10.3389\/fimmu.2021.755639","volume":"12","author":"M Guercio","year":"2021","unstructured":"Guercio M, et al. Inclusion of the Inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell malignancies. Front Immunol. 2021;12:755639.","journal-title":"Front Immunol"},{"key":"1376_CR31","doi-asserted-by":"publisher","first-page":"17230","DOI":"10.1038\/s41598-017-17442-7","volume":"7","author":"I Katano","year":"2017","unstructured":"Katano I, et al. Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse. Sci Rep. 2017;7:17230.","journal-title":"Sci Rep"},{"key":"1376_CR32","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","volume":"100","author":"M Ito","year":"2002","unstructured":"Ito M, et al. NOD\/SCID\/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175\u201382.","journal-title":"Blood"},{"key":"1376_CR33","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.stemcr.2016.05.011","volume":"6","author":"B Sacchetti","year":"2016","unstructured":"Sacchetti B, et al. No identical \u201cmesenchymal stem cells\u201d at different times and sites: human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels. Stem Cell Rep. 2016;6:897\u2013913.","journal-title":"Stem Cell Rep"},{"key":"1376_CR34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1161\/CIRCRESAHA.108.178590","volume":"103","author":"JM Melero-Martin","year":"2008","unstructured":"Melero-Martin JM, et al. Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res. 2008;103:194\u2013202.","journal-title":"Circ Res"},{"key":"1376_CR35","doi-asserted-by":"publisher","first-page":"659253","DOI":"10.3389\/fonc.2021.659253","volume":"11","author":"N van Gils","year":"2021","unstructured":"van Gils N, Denkers F, Smit L. Escape from treatment; the different faces of leukemic stem cells and therapy resistance in acute myeloid leukemia. Front Oncol. 2021;11:659253.","journal-title":"Front Oncol"},{"key":"1376_CR36","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1182\/blood-2011-10-384362","volume":"120","author":"C Bergamaschi","year":"2012","unstructured":"Bergamaschi C, et al. Circulating IL-15 exists as heterodimeric complex with soluble IL-15Ralpha in human and mouse serum. Blood. 2012;120:e1-8.","journal-title":"Blood"},{"key":"1376_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-S2-P398","author":"F Concha-Benavente","year":"2015","unstructured":"Concha-Benavente F, Benjamin Kansy RMS, Ferris RL. PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer. J ImmunoTher Cancer. 2015. https:\/\/doi.org\/10.1186\/2051-1426-3-S2-P398.","journal-title":"J ImmunoTher Cancer"},{"key":"1376_CR38","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3324\/haematol.2018.208751","volume":"104","author":"KD Cummins","year":"2019","unstructured":"Cummins KD, Gill S. Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality? Haematologica. 2019;104:1302\u20138.","journal-title":"Haematologica"},{"key":"1376_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bjh.12282","volume":"161","author":"S Tettamanti","year":"2013","unstructured":"Tettamanti S, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161:389\u2013401.","journal-title":"Br J Haematol"},{"key":"1376_CR40","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359.","journal-title":"N Engl J Med"},{"key":"1376_CR41","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322\u201331.","journal-title":"Blood"},{"key":"1376_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112259","author":"E Laborda","year":"2017","unstructured":"Laborda E, et al. Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18112259.","journal-title":"Int J Mol Sci"},{"key":"1376_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2020.271908","volume":"107","author":"M Gurney","year":"2022","unstructured":"Gurney M, et al. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. Haematologica. 2022;107:437\u201345.","journal-title":"Haematologica"},{"key":"1376_CR44","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.7150\/jca.28952","volume":"10","author":"H Salman","year":"2019","unstructured":"Salman H, et al. Preclinical targeting of human acute myeloid leukemia using CD4-specific chimeric antigen receptor (CAR) T cells and NK cells. J Cancer. 2019;10:4408\u201319.","journal-title":"J Cancer"},{"key":"1376_CR45","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang X, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8:1083\u20139.","journal-title":"Am J Cancer Res"},{"key":"1376_CR46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","volume":"8","author":"C Zhang","year":"2017","unstructured":"Zhang C, et al. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. 2017;8:533.","journal-title":"Front Immunol"},{"key":"1376_CR47","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","volume":"96","author":"F Vergez","year":"2011","unstructured":"Vergez F, et al. High levels of CD34+CD38low\/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a groupe ouest-est des leucemies aigues et maladies du sang (GOELAMS) study. Haematologica. 2011;96:1792\u20138.","journal-title":"Haematologica"},{"key":"1376_CR48","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3324\/haematol.2014.103580","volume":"99","author":"C Bueno","year":"2014","unstructured":"Bueno C, et al. Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease. Haematologica. 2014;99:1168\u201375.","journal-title":"Haematologica"},{"key":"1376_CR49","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1084\/jem.20091050","volume":"206","author":"P Menendez","year":"2009","unstructured":"Menendez P, et al. Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med. 2009;206:3131\u201341.","journal-title":"J Exp Med"},{"key":"1376_CR50","doi-asserted-by":"publisher","first-page":"34056","DOI":"10.18632\/oncotarget.26118","volume":"9","author":"AM Zahran","year":"2018","unstructured":"Zahran AM, et al. Survival outcomes of CD34(+)CD38(-)LSCs and their expression of CD123 in adult AML patients. Oncotarget. 2018;9:34056\u201365.","journal-title":"Oncotarget"},{"key":"1376_CR51","doi-asserted-by":"crossref","unstructured":"Baroni ML et al. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. J Immunother Cancer. 2020; 8.","DOI":"10.1136\/jitc-2020-000845"},{"key":"1376_CR52","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40425-019-0564-6","volume":"7","author":"R Nguyen","year":"2019","unstructured":"Nguyen R, et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer. 2019;7:81.","journal-title":"J Immunother Cancer"},{"key":"1376_CR53","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma. J Clin Oncol. 2020;38:3794\u2013804.","journal-title":"J Clin Oncol"},{"key":"1376_CR54","doi-asserted-by":"crossref","unstructured":"Christodoulou I et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother Cancer. 2021; 9.","DOI":"10.1101\/2021.09.23.461509"},{"key":"1376_CR55","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fimmu.2020.00167","volume":"11","author":"M Khan","year":"2020","unstructured":"Khan M, Arooj S, Wang H. NK cell-based immune checkpoint inhibition. Front Immunol. 2020;11:167.","journal-title":"Front Immunol"},{"key":"1376_CR56","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. 2017;7:e1364828.","journal-title":"Oncoimmunology"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01376-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01376-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01376-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T12:06:00Z","timestamp":1667736360000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01376-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,5]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01376-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,5]]},"assertion":[{"value":"22 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from each donor. The studies were approved by the Institutional Ethical Committee N 2553_OPBG_2021. Mouse experiments were conducted in compliance with the international, EU and national ethical requirements and were approved by the Italian Health Ministry (N\u00b088\/2016-PR and n.\u00a0238\/2022-PR 12\/4\/2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicting financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}